 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || yiqibuvir (HEC110114) / HEC Pharm
Trial completion: ADME Study of [14C] Yiqibuvir in Healthy Male Subjects (clinicaltrials.gov) - Feb 21, 2024
P1, N=8, Completed, Sponsor: Sunshine Lake Pharma Co., Ltd.
Not yet recruiting --> Completed
- yiqibuvir (HEC110114) / HEC Pharm
Antaitasvir plus Yiqibuvir for treatment of chronic hepatitis C virus infection: a phase 2/3 study (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_2209;
Not yet recruiting --> Completed Treatment with the pan-genotypic regimen of antaitasvir plus yiqibuvir for 12 weeks was highly effective and safe in subjects infected with HCV.
- || yiqibuvir (HEC110114) / HEC Pharm
New P1 trial: ADME Study of [14C] Yiqibuvir in Healthy Male Subjects (clinicaltrials.gov) - Aug 18, 2023
P1, N=8, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- |||| yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
Trial completion date, Trial primary completion date, Combination therapy: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C (clinicaltrials.gov) - Apr 12, 2023
P2/3, N=520, Recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
Treatment with the pan-genotypic regimen of antaitasvir plus yiqibuvir for 12 weeks was highly effective and safe in subjects infected with HCV. Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- || yiqibuvir (HEC110114) / HEC Pharm
Trial completion: Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 (clinicaltrials.gov) - Dec 21, 2022
P1, N=14, Completed, Sponsor: Sunshine Lake Pharma Co., Ltd.
Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023 Recruiting --> Completed
- || yiqibuvir (HEC110114) / HEC Pharm
Enrollment open: Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 (clinicaltrials.gov) - Oct 26, 2022
P1, N=14, Recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- || yiqibuvir (HEC110114) / HEC Pharm
New P1 trial: Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 (clinicaltrials.gov) - Aug 17, 2022
P1, N=14, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- |||||||||| yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
New P2/3 trial, Combination therapy: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C (clinicaltrials.gov) - May 26, 2022
P2/3, N=520, Recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- || yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
Trial completion: Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (clinicaltrials.gov) - Nov 5, 2020
P1, N=28, Completed, Sponsor: Sunshine Lake Pharma Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- || yiqibuvir (HEC110114) / HEC Pharm
Trial completion: The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (clinicaltrials.gov) - Sep 9, 2020
P1/2, N=24, Completed, Sponsor: Sunshine Lake Pharma Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Completed
- || yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
Enrollment open: Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (clinicaltrials.gov) - Aug 7, 2020
P1, N=28, Recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- || yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
Trial initiation date: Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (clinicaltrials.gov) - May 27, 2020
P1, N=28, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
Not yet recruiting --> Recruiting Initiation date: Apr 2020 --> Jul 2020
- | yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
Trial completion date, Trial primary completion date: Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (clinicaltrials.gov) - Mar 18, 2020
P1, N=28, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
Initiation date: Apr 2020 --> Jul 2020 Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Apr 2020 --> Jul 2020
- ||| yiqibuvir (HEC110114) / HEC Pharm
Trial completion: The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Mar 18, 2020
P1, N=93, Completed, Sponsor: Sunshine Lake Pharma Co., Ltd.
Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Apr 2020 --> Jul 2020 Recruiting --> Completed
- || yiqibuvir (HEC110114) / HEC Pharm, antaitavir hasophate (HEC74647PA) / HEC Pharm
New P1 trial: Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (clinicaltrials.gov) - Jan 18, 2020
P1, N=28, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- || yiqibuvir (HEC110114) / HEC Pharm
New P1/2 trial: The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (clinicaltrials.gov) - Dec 17, 2019
P1/2, N=24, Not yet recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.
- ||| yiqibuvir (HEC110114) / HEC Pharm
New P1 trial: The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Apr 3, 2019
P1, N=116, Recruiting, Sponsor: Sunshine Lake Pharma Co., Ltd.